Daniel W. Bougie

3.1k total citations
61 papers, 2.0k citations indexed

About

Daniel W. Bougie is a scholar working on Hematology, Surgery and Genetics. According to data from OpenAlex, Daniel W. Bougie has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 29 papers in Surgery and 24 papers in Genetics. Recurrent topics in Daniel W. Bougie's work include Platelet Disorders and Treatments (45 papers), Heparin-Induced Thrombocytopenia and Thrombosis (29 papers) and Blood disorders and treatments (24 papers). Daniel W. Bougie is often cited by papers focused on Platelet Disorders and Treatments (45 papers), Heparin-Induced Thrombocytopenia and Thrombosis (29 papers) and Blood disorders and treatments (24 papers). Daniel W. Bougie collaborates with scholars based in United States, Canada and Australia. Daniel W. Bougie's co-authors include Richard H. Aster, Brian R. Curtis, Brian R. Curtis, Janice G. McFarland, Peter R. Wilker, Curtis G. Jones, James N. George, Anand Padmanabhan, Demin Wang and Jessica Reese and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Chemical Society and Journal of Clinical Investigation.

In The Last Decade

Daniel W. Bougie

58 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel W. Bougie United States 22 1.2k 950 367 261 248 61 2.0k
Nils U. Bang United States 30 1.2k 1.0× 316 0.3× 152 0.4× 38 0.1× 460 1.9× 90 2.6k
Peter Hellstern Germany 28 1.1k 0.9× 328 0.3× 89 0.2× 94 0.4× 500 2.0× 115 2.6k
Mark Blostein Canada 28 445 0.4× 413 0.4× 88 0.2× 37 0.1× 607 2.4× 81 2.2k
J. Vermylen Belgium 31 1.1k 0.9× 533 0.6× 185 0.5× 14 0.1× 486 2.0× 110 2.6k
Douglas J. Christie United States 21 651 0.5× 303 0.3× 176 0.5× 17 0.1× 467 1.9× 46 1.3k
Marc Verstraete Belgium 30 651 0.5× 828 0.9× 83 0.2× 64 0.2× 1.1k 4.3× 133 2.7k
T W Barrowcliffe United Kingdom 27 1.1k 0.9× 549 0.6× 48 0.1× 51 0.2× 710 2.9× 80 2.5k
Luciana Teofili Italy 30 1.1k 0.9× 218 0.2× 159 0.4× 72 0.3× 88 0.4× 147 2.6k
Kathleen E. Brummel United States 12 887 0.7× 324 0.3× 33 0.1× 71 0.3× 505 2.0× 14 1.7k
F Duckert Switzerland 26 1.1k 0.9× 377 0.4× 67 0.2× 39 0.1× 340 1.4× 121 2.4k

Countries citing papers authored by Daniel W. Bougie

Since Specialization
Citations

This map shows the geographic impact of Daniel W. Bougie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel W. Bougie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel W. Bougie more than expected).

Fields of papers citing papers by Daniel W. Bougie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel W. Bougie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel W. Bougie. The network helps show where Daniel W. Bougie may publish in the future.

Co-authorship network of co-authors of Daniel W. Bougie

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel W. Bougie. A scholar is included among the top collaborators of Daniel W. Bougie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel W. Bougie. Daniel W. Bougie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sulaeman, Hasan, Eduard Grebe, Honey Dave, et al.. (2023). Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications. Microbiology Spectrum. 11(4). e0323422–e0323422. 8 indexed citations
2.
Bougie, Daniel W., Sarah E. Reese, Rebecca Birch, et al.. (2023). Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion. 63(5). 960–972. 9 indexed citations
3.
Bougie, Daniel W., et al.. (2019). Cross-Reactivity of Drug-Dependent Antibodies in Patients with Immune Thrombocytopenia Induced By Beta-Lactam Antibiotics. Blood. 134(Supplement_1). 2350–2350. 2 indexed citations
4.
Padmanabhan, Anand, Shannon M. Pechauer, Curtis G. Jones, Daniel W. Bougie, & Richard H. Aster. (2019). New Monoclonal Antibodies Reveal Distinct Specificities for Platelet Factor 4 Bound to Heparin Vs. Platelets: Implications for HIT Pathogenesis. Blood. 134(Supplement_1). 1144–1144.
5.
6.
Jones, Curtis G., Shannon M. Pechauer, Brian R. Curtis, et al.. (2017). A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies. CHEST Journal. 152(4). e77–e80. 17 indexed citations
7.
Padmanabhan, Anand, Curtis G. Jones, Shannon M. Pechauer, et al.. (2017). IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. CHEST Journal. 152(3). 478–485. 92 indexed citations
8.
Padmanabhan, Anand, Curtis G. Jones, Shannon M. Pechauer, et al.. (2016). A Novel PF4-Dependent P-Selectin Expression Assay (PEA) Facilitates Early Detection of Pathogenic HIT Antibodies: Implications for Diagnosis and Treatment of HIT. Blood. 128(22). 2599–2599. 1 indexed citations
9.
Padmanabhan, Anand, Curtis G. Jones, Brian R. Curtis, et al.. (2016). A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. CHEST Journal. 150(3). 506–515. 70 indexed citations
10.
11.
Reese, Jessica, Daniel W. Bougie, Brian R. Curtis, et al.. (2015). Drug‐induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin. American Journal of Hematology. 90(5). 406–410. 85 indexed citations
12.
13.
Bougie, Daniel W., Julie A. Peterson, Adam J. Kanack, Brian R. Curtis, & Richard H. Aster. (2013). Antibodies Specific For Human Neutrophil Antigen 3a (HNA-3a) Recognize Complex Epitopes On Choline Transporter Protein 2 (CTL2): Implications For HNA-3a Antibody Detection. Blood. 122(21). 3662–3662. 1 indexed citations
14.
Zhu, Jieqing, Won Suk Choi, Ana Negri, et al.. (2012). Structure-Guided Design of a High-Affinity Platelet Integrin α IIb β 3 Receptor Antagonist That Disrupts Mg 2+ Binding to the MIDAS. Science Translational Medicine. 4(125). 125ra32–125ra32. 73 indexed citations
15.
16.
Bougie, Daniel W., et al.. (2009). Drug Metabolites Produced In Vivo Promote Clearance of Human Platelets by Metabolite-Specific Antibodies in NOD/Scid Mice.. Blood. 114(22). 2408–2408. 1 indexed citations
17.
Drygalski, Annette von, Brian R. Curtis, Daniel W. Bougie, et al.. (2007). Vancomycin-Induced Immune Thrombocytopenia. New England Journal of Medicine. 356(9). 904–910. 151 indexed citations
18.
Aster, Richard H. & Daniel W. Bougie. (2007). Drug-Induced Immune Thrombocytopenia. New England Journal of Medicine. 357(6). 580–587. 369 indexed citations
19.
Bougie, Daniel W., Peter R. Wilker, & Richard H. Aster. (2006). Patients with quinine-induced immune thrombocytopenia have both “drug-dependent” and “drug-specific” antibodies. Blood. 108(3). 922–927. 77 indexed citations
20.
Aster, Richard H., Brian R. Curtis, Daniel W. Bougie, et al.. (2006). Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Journal of Thrombosis and Haemostasis. 4(3). 678–679. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nils U. Bang Breakdown of academic impact, for papers by Peter Hellstern Breakdown of academic impact, for papers by Mark Blostein Breakdown of academic impact, for papers by J. Vermylen Breakdown of academic impact, for papers by Douglas J. Christie Breakdown of academic impact, for papers by Marc Verstraete Breakdown of academic impact, for papers by T W Barrowcliffe Breakdown of academic impact, for papers by Luciana Teofili Breakdown of academic impact, for papers by Kathleen E. Brummel Breakdown of academic impact, for papers by F Duckert
Rankless by CCL
2026